U.S. Hospitality Stock News

We wouldn't blame Gulfport Energy Corporation ( NYSE:GPOR ) shareholders if they were a little worried about the fact...

Looking at Silence Therapeutics plc's ( NASDAQ:SLN ) insider transactions over the last year, we can see that insiders...

Hurco Companies (HURC) closed FY 2025 with fourth quarter revenue of US$45.5 million and a basic EPS loss of US$0.48, while trailing twelve month revenue stood at US$178.6 million against a basic EPS loss of US$2.34. Over recent periods, the company has seen quarterly revenue move between US$40.9 million and US$53.7 million, with basic EPS losses ranging from US$0.22 to US$1.47. This sets a clear backdrop of pressure on profitability that keeps margins front and center for investors assessing...

LENZ Therapeutics (LENZ) shares are in focus after the company signed an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its VIZZ eye drop for presbyopia across multiple Middle Eastern markets. See our latest analysis for LENZ Therapeutics. The distribution deal comes after a weak run for the stock, with a 30 day share price return of 40.62% and a 90 day share price return of 61.67%, while the 1 year total shareholder return sits at...

If you are wondering whether JBT Marel at US$156.04 is still a sensible entry point or more of a hold, the next sections will walk through what the current price may be implying about value. The stock has recorded returns of 3.6% over the past week, 1.5% over the last month, 3.6% year to date and 28.5% over the past year, with a 55.0% return over three years and 25.8% over five years. These figures can affect how investors think about both upside potential and downside risk. Recent attention...

Interface (NASDAQ:TILE) has had a great run on the share market with its stock up by a significant 15% over the last...

CVD Equipment Corporation ( NASDAQ:CVV ) shareholders have had their patience rewarded with a 36% share price jump in...

Angi Inc.'s ( NASDAQ:ANGI ) price-to-earnings (or "P/E") ratio of 17.2x might make it look like a buy right now...

Despite an already strong run, Astronics Corporation ( NASDAQ:ATRO ) shares have been powering on, with a gain of 28...

Let's talk about the popular Charles River Laboratories International, Inc. ( NYSE:CRL ). The company's shares saw a...

While Townsquare Media, Inc. ( NYSE:TSQ ) might not have the largest market cap around , it received a lot of attention...

Diversification is a key tool for dealing with stock price volatility. But the goal is to pick stocks that do better...

Lam Research Corporation ( NASDAQ:LRCX ) shares have continued their recent momentum with a 30% gain in the last month...

Insiders were net sellers of Optimum Communications, Inc.'s ( NYSE:OPTU ) stock during the past year. That is, insiders...

Alamo Group Inc.'s ( NYSE:ALG ) dividend will be increasing from last year's payment of the same period to $0.34 on...

If you are wondering whether N-able's share price around US$7.31 actually reflects its underlying worth, you are not alone. This article is built to help you size that up clearly. Over the past week the stock is roughly flat at a 0.1% return, but that sits against a 4.2% decline over 30 days and a 19.7% decline over the past year, which can change how investors view both its potential and its risks. Recent coverage has focused on how N-able is positioned within the broader software and IT...

If you have been wondering whether P10 is priced attractively right now, you are not alone. Many investors are asking the same question about what they are really paying for with this stock. P10 shares last closed at US$10.33, with recent returns of 4.4% over the past week, 1.2% over the past month, 4.4% year to date, and a 17.6% decline over the past year and 7.6% decline over three years. Recent market attention on P10 has been shaped by ongoing discussion around its role in the...

Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026. A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...

If you are wondering whether Banco Latinoamericano de Comercio Exterior S. A is still attractively priced after its recent run, this article will walk through what the current share price might imply about value. The stock closed at US$43.45, with returns of 26.7% over the past year, even though the last 7 days and 30 days saw returns of a 0.8% decline and a 3.5% decline respectively. Recent interest around BLX has largely centered on its role as a specialist trade finance bank for Latin...

What triggered the latest Teleflex stock reaction Teleflex (TFX) shares moved after the company cut its 2025 revenue outlook and announced leadership changes, including the departure of long standing CEO Liam Kelly and the appointment of interim CEO Stuart Randle. See our latest analysis for Teleflex. Those guidance cuts and leadership changes came after a weaker patch, with a 30 day share price return of 11.35% and a 1 year total shareholder return decline of 34.67%, showing momentum has...

If you are wondering whether Liquidia's share price still offers value after a strong run, the starting point is understanding how its current market price lines up with different ways of estimating worth. Liquidia's stock closed at US$35.86, with returns of 14.2% over the past week, 9.7% over the past month and 14.2% year to date, while the 1 year return sits at 194.2% and the 3 year return is very large. Recent attention on Liquidia has centered on its position in pharmaceuticals and...

What triggered the latest move in Pacira BioSciences? Pacira BioSciences (PCRX) has drawn attention after reporting record EXPAREL sales with 7% volume growth in what it called its strongest fourth quarter in three years, along with a completed fourth quarter share repurchase and fresh activist pressure on the board. See our latest analysis for Pacira BioSciences. Despite record EXPAREL sales and a completed buyback that retired 13.28% of shares under the May 2025 program, Pacira BioSciences’...

If you are wondering whether uniQure's share price lines up with its underlying value, this article walks through the key numbers so you can judge for yourself. Over the past year, uniQure's stock has returned 82.8%, with shorter term moves of 8.3% over 7 days and 25.7% over 30 days from a last close of US$25.32. These shifts can affect how investors think about both upside and risk. Recent news around uniQure has focused on its gene therapy pipeline and partnerships, which helps explain why...

If you are wondering whether Edison International is offering fair value right now, it helps to step back and line up what the recent share performance and fundamentals are actually telling you. The stock last closed at US$60.99, with returns of 0.1% over 7 days, 6.1% over 30 days, 0.1% year to date, 0.3% decline over 1 year, 3.5% over 3 years, and 24.7% over 5 years. Taken together, these figures give a mixed picture of how the market has been pricing the company over different time...